Fluidigm to Participate in the Cantor Virtual Global Healthcare Conference
Fluidigm Corporation (Nasdaq:FLDM) announced its participation in the Cantor Virtual Global Healthcare Conference on September 28, 2021. CEO Chris Linthwaite and CFO Vikram Jog will share updates on the company’s business strategy and financial performance at 2:00 p.m. ET. A live webcast of the event will be available on the Fluidigm investor website, with an archived replay accessible for 90 days.
The company focuses on advancing translational and clinical research through innovative biotechnology tools.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will participate in investor meetings and present updates regarding Fluidigm’s business strategy and financial performance at the following investor event:
Cantor Virtual Global Healthcare Conference
Tuesday, September 28, 2021
Fluidigm presentation at 2:00 p.m. ET, 11:00 a.m. PT
A live webcast of the company’s presentation and subsequent replay will be available in the Events & Presentations section of the Fluidigm® investor website. The webcast will be archived for 90 days following the live presentation.
About Fluidigm
Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.
Patent information and Limited Use Label License: Fluidigm.com/legal/notices. Fluidigm, the Fluidigm logo, Advanta, and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation or its subsidiaries in the United States and/or other countries. All other trademarks are the sole property of their respective owners. The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is for In Vitro Diagnostic Use. It is for Use under Emergency Use Authorization Only. Rx Only. Other Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
Available Information
We use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Contacts:
Investors:
Peter DeNardo
415 389 6400
ir@fluidigm.com
Media:
Mark Spearman
Senior Director, Corporate Communications
650 243 6621
mark.spearman@fluidigm.com
FAQ
What event is Fluidigm participating in on September 28, 2021?
What time will Fluidigm's presentation take place during the conference?
Who will represent Fluidigm at the conference?
Where can I watch the replay of Fluidigm's presentation?
What is the focus of Fluidigm’s research and tools?
